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The femalemammary gland is a very dynamic organ that undergoes continuous tissue remodeling during adulthood.
Although it is well established that the number of menstrual cycles and pregnancy (in this case transiently) increase
the risk of breast cancer, the reasons are unclear. Growing clinical and experimental evidence indicates that im-
proper involution plays a role in the development of this malignancy. Recently, we described the miR-424(322)/503
cluster as an important regulator of mammary epithelial involution after pregnancy. Here, through the analysis of
∼3000 primary tumors, we show that miR-424(322)/503 is commonly lost in a subset of aggressive breast cancers
and describe the genetic aberrations that inactivate its expression. Furthermore, through the use of a knockout
mouse model, we demonstrate for the first time that loss of miR-424(322)/503 promotes breast tumorigenesis in
vivo. Remarkably, we found that loss of miR-424(322)/503 promotes chemoresistance due to the up-regulation of
two of its targets: BCL-2 and insulin-like growth factor-1 receptor (IGF1R). Importantly, targeted therapies blocking
the aberrant activity of these targets restore sensitivity to chemotherapy. Overall, our studies reveal miR-424(322)/
503 as a tumor suppressor in breast cancer and provide a link between mammary epithelial involution, tumori-
genesis, and the phenomenon of chemoresistance.
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In animals, the regulation of every cell must be exquisite-
ly orchestrated in order to support the viability of the
whole organism. Genetic alterations that accumulate in
genes such as tumor suppressors and oncogenes in indi-
vidual cells can lead to the disruption of normal biological
processes and promote tumorigenesis.
The female mammary gland is a very dynamic organ
that undergoes continuous tissue remodeling during
adulthood (Howard and Gusterson 2000; Ip and Asch
2000;Macias andHinck 2012). These processes are tightly
regulated in time and space to ensure proper organ func-
tion and avoid pathological consequences. During regular
ovarian cycles, there is an increase in the mammary epi-
thelial content of the mammary gland that serves to pre-
pare the mammary gland for a potential pregnancy. In
the absence of pregnancy, the diestrus phase terminates
with the regression of the mammary epithelium to its
basal state. If pregnancy occurs, the mammary gland un-
dergoesmassive tissue remodeling, and lactiferous alveoli
invade nearly the entiremammary fat pad. After weaning,
regression of this architecture leads to alveolar and secre-
tory duct collapse, a process known as involution (Watson
2006; Stein et al. 2007). Although it is well established
that the number ofmenstrual cycles (Collaborative Group
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on Hormonal Factors in Breast Cancer 2012) and pregnan-
cy (in this case, transiently) (Lambe et al. 1994) increase
the risk of breast cancer, the reasons are unclear. Growing
clinical and experimental evidence indicates that improp-
er involution plays a role in the development of thismalig-
nancy (Watson 2006; Radisky and Hartmann 2009). Not
surprisingly, some of the pathways described to have a
role in this process are also involved in tumorigenesis.
Two main discrete phases of involution have been de-
scribed. The first phase is initiated by milk stasis and
the release of soluble factors such as TGF-β (Nguyen and
Pollard 2000; Bierie et al. 2009) and IL-6 cytokine family
members LIF (Kritikou et al. 2003) and OSM (Tiffen et
al. 2008). These activate STAT3 (Chapman et al. 1999;
Kreuzaler et al. 2011; Sargeant et al. 2014), NF-κB (Baxter
et al. 2006), and insulin-like growth factor (IGF) signal-
ing, (Neuenschwander et al. 1996; Allan et al. 2004),
leading to apoptotic (Jager et al. 1997; Walton et al.
2001; Rucker et al. 2011) and nonapoptotic (Kreuzaler
et al. 2011) programmed cell death. During the second
phase, nonepithelial cells are also critical, and macro-
phage function (Hutchins et al. 2012; O’Brien et al.
2012) and high protease activity from the stroma (matrix
metalloproteinases) (Talhouk et al. 1992; Fata et al.
2001; Green and Lund 2005) are required. Despite the
above, overall, our understanding of the molecular mech-
anisms involved in mammary epithelial dynamics is far
from complete. Moreover, how deregulation of specific
genes during involution influences tumorigenesis is poor-
ly understood.
Recently, through the generation of a knockout mouse
model, we discovered that the microRNA (miRNA) clus-
ter miR-424(322)/503 is a TGF-β-induced regulator of in-
volution in the mammary epithelium (Llobet-Navas
et al. 2014a,b). Importantly, the miR-424(322)/503 locus
is commonly lost in a subset of breast cancers that
have clinicopathological characteristics of poor progno-
sis. This miRNA cluster contains two miRNAs, miR-
424(322) and miR-503, which belong to the miR-16 fam-
ily and consequently can modulate the expression of the
same target genes (Liu et al. 2008; Finnerty et al. 2010).
Our studies demonstrated that part of the biological ac-
tivity of miR-424(322)/503 in the mammary epithelium
is mediated by its ability to down-regulate the expression
of CDC25A, BCL-2, and IGF-1 receptor (IGF1R). Notably,
these three genes have been found to be overexpressed in
human breast cancers presenting oncogenic functions
(CDC25A [Cangi et al. 2000], IGF1R [Kucab and Dunn
2003], and BCL-2 [Dawson et al. 2010]). Furthermore,
up-regulation of BCL-2 (Dawson et al. 2010; Colitti
2012; Vaillant et al. 2013) and IGF1R signaling (Kucab
and Dunn 2003; Hendrickson and Haluska 2009; Vu
and Claret 2012) is a common and well-established
mechanism that cancer cells, including breast cancers,
use to overcome apoptosis induced by chemotherapy.
Thus, based on the above findings, we aimed to investi-
gate a putative tumor suppressor function for the
miR-424(322)/503 cluster and specifically the impact
that loss of this miRNA cluster has on response to
chemotherapy.
Results
The miR-424(322)/503 cluster is lost in breast cancers
Our previous studies revealed that miR-424(322)/503−/−
female mice present defects in mammary gland involu-
tion and display alveolar hyperplasia after pregnancy (Llo-
bet-Navas et al. 2014a). Thus, we decided to investigate a
putative tumor suppressor role for this miRNA cluster in
breast cancer. First, we pooled theMETABRIC (Molecular
Taxonomy of Breast Cancer International Consortium)
(Curtis et al. 2012) and the BRCA-The Cancer Genome
Atlas (TCGA) (The Cancer Genome Atlas Network
2012) data sets, which are the two largest data sets con-
taining matched DNA copy number alteration (CNA)
and expression analysis (coding genes andmiRNAs) of pri-
mary breast cancers. We then analyzed the 2165 prether-
apeutic samples from patients with nonmetastatic
primary invasive breast cancer who underwent surgery
and had available follow-up data (Supplemental Table
S1). In each data set, themiR-424(322)503 locus was delet-
ed in ∼14% of breast cancers, and its deletion correlated
with lower expression levels of the mature miR-424 and
miR-503 forms (Fig. 1A). Although small deletions (<2
Mb) occurred, the majority was chromosomal arm losses
resulting in heterozygosis (Ht) (Fig. 1A).
We then searched for correlations between miR-424
(322)/503 status (302 cases with and 1863 cases without
deletion, referred to here as miR-DEL and miR-non-DEL,
respectively) and the clinicopathological and molecular
characteristics of the tumors. Loss of miR-424(322)/503
was associated with poor prognosis characteristics such
as high-grade (histological and genomic-grade index
[GGI]) (Sotiriou et al. 2006) larger pathological tumor
size, triple-negative (TN) status, strong cell proliferation
(KI67 mRNA expression), and GGI signature (Fig. 1B;
Supplemental Table S2). Commonly, primary breast can-
cers are also stratified into different molecular subtypes
based on genome-wide studies of mRNA expression and
CNAs (Perou et al. 2000; Curtis et al. 2012). We found
that deletion of this miR cluster was more frequent in tu-
mor subtypes with aggressive behavior such as basal and
luminal B (Fig. 1C) and the integrative clusters 1, 2, 6, 9,
and 10 (Supplemental Fig. S1A).
Based on its association with poor prognosis character-
istics, we hypothesized that loss of the miR-424(322)/503
cluster could influence patient survival. The median fol-
low-up was 63 mo (range 1–302), during which 1711 pa-
tients remained alive, and 454 patients died. The 5-yr
overall survival was 84% (95% CI 82–86). The “miR-
DEL” subgroup was associated with shorter overall sur-
vival in the whole population, with 75% 5-yr overall sur-
vival (95% CI 70–81) versus 85% (95% CI 83–87) for the
“miR-non-DEL” subgroup (P = 3.60 × 10−4, log-rank test)
(Fig. 1D; Supplemental Table S3). A similar result was ob-
served in basal tumors, in which the 5-yr overall survival
was 55% (95% CI 43–69) in the case of miR deletion and
76% (95% CI 71–82) in the absence of deletion (P =
4.01 × 10−3, log-rank test) (Fig. 1D; Supplemental Fig.
S1B; Supplemental Table S3). No prognostic valuewas ob-
served in the othermolecular subtypes (Supplemental Fig.
Rodriguez-Barrueco et al.
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Figure 1. miR-424(322)/503 is lost in breast cancer and is associated with poor prognosis and aggressive subtypes. (A) Copy number pro-
file of the X chromosome in human breast cancers (METABRIC plus TCGA data sets), highlighting the chromosomal region containing
the miR-424(322)/503 locus. The correlation between copy number and expression for surrounding genes is included at the bottom. The
bar graph and box plots show the number of breast cancers presenting deletion (DEL) of the miR-424(322)/503 locus as well as the asso-
ciation between copy number and expression for miR-424(322) andmiR-503. The bar graphs show the association between deletion of the
miR-424(322)/503 locuswith grade (B) and PAM50molecular subtypes (C ). (D) Overall survival of breast cancer patientswith andwithout
deletion of the miR-424(322)/503 locus (all patients and basal tumors are shown). (E) ThemiR-424(322)/503 cluster is monoallelically ex-
pressed as shown by sequencing a single-nucleotide polymorphism (SNP) located between the miRNAs in the cluster at the DNA and
RNA level. Chromatin immunoprecipitation (ChIP) assays confirm that the expressed allele is associated with the active transcription
elongation histone mark H3K36me3. (F ) Methylation status analysis of the miR-424(322)/503 locus in breast cancers (TCGA-BRCA
data set) with and without deletion of the locus. Each dot represents an individual primary tumor.
miR-424/503 is a breast cancer tumor suppressor
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S1B; Supplemental Table S3). Inmultivariate analysis, the
“miR-DEL” status retained unfavorable prognostic signif-
icance in the whole population (P = 2.95 × 10−2, Wald test;
hazard ratio [HR] = 1.34 [95% CI 1.03–1.75]) and the basal
subtype (P = 1.4 × 10−2,Wald test; HR = 1.99 [95%CI 1.30–
3.04]) (Supplemental Table S3).
ThemiR-424(322)/503 locus is located on theXchromo-
some, andwehypothesized that, due to X chromosome in-
activation, it may be monoallelically expressed in cells of
female origin. In this case, the commonly found Ht dele-
tion of this locus would be sufficient to abrogate the ex-
pression of the miRNA cluster if the active allele is the
target of the deletion. Thus, we studied the expression of
a single-nucleotide polymorphism (SNP) located between
miR-424 and miR-503 in the primary miRNA (pri-
miRNA) (Fig. 1E) in normal human mammary epithelial
cell lines (diploid for the X chromosome). Genomic DNA
and RNA extraction followed by PCR/RT–PCR and
sequencing revealed thatwhileMCF-10Acells and twodif-
ferent immortalizedHuMEC(humanmammaryepithelial
cell) clones were homozygous for the SNP (data not
shown), 184B5 cells were heterozygous and presented the
T/C polymorphism in the genomic DNA (Fig. 1E). As pre-
dicted, expression studies showed that only one of the two
alleles was expressed in 184B5 cells (Fig. 1E). To further
demonstrate that the expressed allele was located on the
active X chromosome (Xa), we performed chromatin im-
munoprecipitation (ChIP) followed by sequencing (ChIP-
seq) using antibodies forH3K36me3, amark of active tran-
scription (Bannister and Kouzarides 2011). As expected,
only the expressed allele was found to be associated with
this histone mark (Fig. 1E). Overall, the above confirmed
that, in mammary epithelial cells of female origin, miR-
424(322)/503 is monoallelically expressed.
Finally, we investigated which of the two miR-424
(322)/503 alleles (active or inactive) was targeted by the
deletion observed in breast cancers. DNA hypermethyla-
tion is linked with the inactive X chromosome (Xi), while
hypomethylation is seen at the Xa (Heard 2004; Briggs and
Reijo Pera 2014); we reasoned that deletion of the active
allele would increase the level of methylation detected
at the miR-424(322)/503 locus by methylation arrays.
Thus, we integrated the methylation profiles and the
CNA data available in the TCGA-BRCA database (The
Cancer Genome Atlas Network 2012). This study re-
vealed that breast cancers with deletions in the miR-424
(322)/503 locus present a significantly higher level of
methylation (Fig. 1F). This result supports the notion
that the active allele is selectively deleted, whereas the
methylated inactive allele remains intact.
miR-424(322)/503−/− female mice develop mammary
tumors that are promoted by pregnancy
We previously described the generation of a C57BL/6/
miR-424(322)/503−/− mouse model (Llobet-Navas et al.
2014a). However, the inbred FVB strain presents enhanced
sensitivity to tumorigenesis and is favored for cancer-re-
lated studies (Davie et al. 2007). To further investigate
the role of this miRNA cluster in carcinogenesis, we first
crossed our C57BL/6/miR-424(322)/503−/− model with
wild-type FVB mice for more than six generations to pro-
duce a >98.5% clean FVB/miR-424(322)/503−/− back-
ground (Supplemental Fig. S2A). All experiments in this
study were done in the FVB background, and we refer to
them here as the miR-424(322)/503−/− model. Next, the
mammary epithelia of >1-yr-old FVB wild-type, miR-424
(322)/503+/−, and miR-424(322)/503−/− virgin females
were evaluated by carmine red staining (Fig. 2A) and
H&E staining (Fig. 2B). Remarkably, while none of the
wild-type animals presented mammary epithelial abnor-
malities, all of themiR-424(322)/503−/− females displayed
enlargement of the terminal ductal lobular units, and
we were able to detect microscopic invasive carcinomas
in 50% of them (Fig. 2E). Heterozygous miR-424(322)/
503+/− animals presented an intermediate phenotype
where hyperplasia predominated (Fig. 2E). Ki-67 immuno-
histochemistry (IHC) revealed that these lesions present-
ed a higher proliferative index than the mammary
epithelia of wild-type animals (Fig. 2B,E).
Because the miR-424(322)/503 cluster has a known role
in post-lactational mammary involution (Llobet-Navas
et al. 2014a) and we showed previously that pregnancy
promotes accumulation of abnormalities in the mamma-
ry epithelium of knockout animals, we next investigated
the development of breast carcinomas in parous miR-
424(322)/503−/− females. Carmine red staining (Fig. 2C)
and H&E staining (Fig. 2D) of mammary glands from >1-
yr-old parous mice that passed through one round of preg-
nancy between the ages of 4 and 7 mo showed a very en-
larged mammary epithelium in miR-424(322)/503−/−
animals, with a large majority of the animals (73%)
presenting microscopic invasive carcinomas (Fig. 2E). Al-
though the majority of the invasive lesions was micro-
scopic, palpable tumors developed in a small fraction of
the animals (two out of 40). Overall, these data demon-
strate that loss of miR-424(322)/503 induces mammary
epithelial tumorigenesis that is promoted by pregnancy
(Supplemental Fig. S2B).
CDC25A, BCL-2, and IGF1R oncogenes are up-regulated
in miR-424(322)/503-deficient mammary tumors
The biological functions ofmiRNAs aremediated by their
ability to attenuate the expression of specific mRNAs.
Both miR-424(322) and miR-503 belong to the miR-16
family (Liu et al. 2008; Finnerty et al. 2010), and we
showed previously (Llobet-Navas et al. 2014a,b) that
they target three genes that have been found to be overex-
pressed, presenting oncogenic functions in human breast
cancers (CDC25A [Cangi et al. 2000], IGF1R [Kucab and
Dunn 2003], and BCL-2 [Dawson et al. 2010]). CDC25A
is a key player in the progression of the cell cycle (Nilsson
and Hoffmann 2000). IGF1R is the canonical receptor for
IGF-1 (Pollak 2012). IGF-1 binding leads to the activation
of two main signaling pathways: the PI3K–AKT/PKB and
Ras–MAPK pathways. BCL-2 is the founding member of
the BCL-2 family of apoptosis regulator proteins, and its
key role in the intrinsic apoptosis pathway is well estab-
lished (Colitti 2012). Thus, we investigated the status of
Rodriguez-Barrueco et al.
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these proteins in cancer cells deficient in miR-424(322)/
503. To evaluate the correlation between the expression
of miR-424(322)/503 and these genes in primary tumors,
we analyzed the RPPA (reverse phase protein array) data
available from the TCGA-BRCA database. These data pro-
vide expression levels for ∼200 proteins, including IGF1R
and BCL-2, in >400 primary breast cancers with matched
information regarding miR-424(322) and miR-503 ex-
pression. Remarkably, these studies showed a significant
increase of both IGF1R and BCL-2 protein in breast can-
cers with low expression of miR-424 (Fig. 3A) and miR-
503 (Supplemental Fig. S3A).
Next, we tested in a mouse model of breast cancer how
loss of miR-424(322)/503 impacts the expression of these
targets and influences breast tumorigenesis. As shown be-
fore, loss of the miR-424(322)/503 cluster occurs in differ-
ent breast cancer subtypes, including ErbB2/HER2+
tumors (see Fig. 1C; Supplemental Fig. S1D). Thus, we
crossed our miRNA cluster knockout animals with the
FVB-Tg(MMTV-ErbB2)NK1Mul/J mouse model (referred
to here as MMTV-Neu for simplification) in which an ac-
tivated oncogene HER2 drives tumor formation in the
mammary gland (Supplemental Fig. S3B; Muller et al.
1988). Female MMTV-Neu mice develop multifocal pal-
pable mammary tumors efficiently after pregnancy (Ebbe-
sen et al. 2016). We generated FVB-Tg(MMTV-ErbB2)
NK1Mul/J/miR-424(322)/503−/− animals (MMTV-Neu-
miR_KO) and compared the expression of IGF1R, BCL-2,
and CDC25A in size-matched tumors (0.5–0.8 cc) with
MMTV-Neu animals. Here we found that the expression
of all three miR-424(322)/503 targets was strongly up-reg-
ulated in mammary tumors from MMTV-Neu-miR_KO
animals (Fig. 3B). As expected, the higher expression of
IGF1R led to elevated levels of phospho-IGF1R and phos-
pho-AKT (Fig. 3B). Additionally, the growth of MMTV-
Neu-miR_KO tumors was accelerated (Fig. 3C), and intra-
tumoral Ki-67 immunostaining revealed a significantly
higher proliferation index (Fig. 3D), as observed in clinical
samples. Despite the aforementioned differences, both an-
imal models developed adenocarcinomas that were histo-
logically identical.
Loss of miR-424(322)/503 induces resistance
to anti-cancer therapy due to up-regulation
of BCL-2 and IGF1R
Up-regulation of BCL-2 (Dawson et al. 2010; Colitti 2012)
and IGF1R signaling (Kucab and Dunn 2003; Hendrickson
and Haluska 2009) is a common and well-established
mechanism that cancer cells, including breast cancers,
use to overcome apoptosis induced by chemotherapy. As
the miR-424(322)/503 cluster targets both pathways and
as loss of miR-424(322)/503 in breast cancer patients is as-
sociated with higher protein levels of IGF1R and BCL-2
Figure 2. miR-424(322)/503−/− female
mice develop mammary tumors that are
promoted by pregnancy. (A) Carmine red
staining of mammary glands from >1-yr-
old miR-424(322)/503−/−, miR-424(322)/
503+/−, and miR-424(322)/503+/+ virgins.
(B) H&E and Ki-67 immunostaining of the
samples from A. (C ) Carmine red staining
of mammary glands from >1-yr-old miR-
424(322)/503−/− and miR-424(322)/503+/+
parous females. (D) H&E and Ki-67 immu-
nostaining of the samples fromC. (E) Quan-
tification of the premalignant and
malignant mammary lesions shown in B
and D. χ2 tests and t-tests (Ki-67) were
used to calculate P-values in E; P < 0.05
was considered significant. All mice were
processed during the estrous phase (n≥ 7).
Parous animals had one pregnancy.
miR-424/503 is a breast cancer tumor suppressor
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(Fig. 3A), we anticipated that loss of miR-424(322)/503
may induce resistance to chemotherapeutic drugs.
Because of the clinical relevance of treatment resis-
tance, we decided to investigate the role of miR-424
(322)/503 in this phenomenon. Thus, we compared the re-
sponse to the standard chemotherapeutic drug paclitaxel
between mammary tumors in MMTV-Neu and MMTV-
Neu-miR_KO animals (Fig. 4A). Female mice underwent
one round of pregnancy, and we subsequently followed
the growth of mammary carcinomas. Once themammary
tumormass reached ∼500mm3, these animals were treat-
ed twice per week with an intraperitoneal dose of 6mg/kg
paclitaxel (Domingo-Domenech et al. 2012; Hannesdottir
et al. 2013;Usary et al. 2013), and the response to this anti-
cancer treatment was monitored (Fig. 4B). This study
showed that while MMTV-Neu tumors responded well
to paclitaxel, showing significant shrinkage in just 2 wk,
MMTV-Neu-miR_KO tumors were refractory to this
treatment and continued growing almost at the rate of
the untreated tumors (Fig. 4B; Supplemental Fig. S4A). Ad-
ditionally, evaluation of apoptosis by cleaved Caspase-3
immunostaining in treated samples revealed that
MMTV-Neu-miR_KO tumors presented a significant re-
duction in the level of apoptosis compared with MMTV-
Neu tumors (Fig. 4C).
Next, we reasoned that if high levels of BCL-2 and
IGF1R indeed mediate resistance to chemotherapy in
miR-424(322)/503-deficient breast cancers, then blocking
their activity may restore sensitivity to treatment. Impor-
tantly, small molecule inhibitors that block the BCL-2
and IGF1R oncogenic pathways already exist in clinical
trials. BH3 mimetics that block the anti-apoptotic activi-
ty of BCL-2 proteins have been developed and show con-
siderable promise (Oltersdorf et al. 2005; Witham et al.
2007; Roberts et al. 2012; Vaillant et al. 2013). In patients,
treatment with early-generation inhibitors induced dose-
dependent thrombocytopenia due to unintended targeting
of BCL-XL, leading to loss ofmature platelets (Mason et al.
Figure 3. PrimarymiR-424(322)/503-deficientmammary tumors showaberrant up-regulation of targetsCDC25A, BCL-2, and IGF1R. (A)
RPPA data, available from the TCGA breast cancer database, were studied to correlate protein expression of BCL-2 and IGF1R with ex-
pression of miR-424. Two graphs are shown, comparing the 20% of samples presenting the highest miR-424 expression with the lowest
20% (left) and all samples (right). Red lines have been included as references. (B) Representative Western blots showing the expression
levels of miR-424(322)/503 targets (IGF1R, BCL-2, and CDC25A) in the MMTV-Neu and MMTV-Neu-miR_KO models. The box plots
show quantification of these data. The Western blots also show elevated phosphorylation (activation) of IGF1R and AKT. (C,D) Growth
curves (C ) as well as H&E and Ki-67 immunostaining (D) comparing tumors fromMMTV-Neu andMMTV-Neu-miR_KOmodels. t-tests
were used to calculate P-values; P < 0.05 was considered significant. For the animal studies, five to 10 animals were used per cohort.
Rodriguez-Barrueco et al.
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2007; Bajwa et al. 2012). However, new-generation inhib-
itors such as ABT-199/venetoclax have greater specificity
for BCL-2, thus preventing this issue (Witham et al. 2007;
Vaillant et al. 2013). ABT-199/venetoclax is currently un-
der investigation in multiple phase 2 and phase 3 clinical
trials, mainly for blood-related malignancies, and has
been approved recently by the FDA for treatment of
chronic lymphocytic leukemia (https://clinicaltrials.gov/
ct2/results?term=ABT-199+&Search=Search). Multiple
IGF1R inhibitors, humanized monoclonal antibodies
(mAbs), and small molecule tyrosine kinase inhibitors
(TKIs) have been evaluated in clinical trials (Chen and
Sharon 2013; King et al. 2014). Although their efficacy
in unselected patients has been limited, these targeted ap-
proaches can induce strong anti-tumor activities in select-
ed tumors, including tumors refractory to standard
therapies (Chen and Sharon 2013; King et al. 2014). Nota-
bly, multiple data from experimental models support the
use of these inhibitors in cancer cells with elevated
IGF1R expression and activated IGF-1 signaling (King
et al. 2014). Among the inhibitors, BMS-754807 is one of
the most specific TKIs for which multiple clinical trials
Figure 4. Loss of miR-424(322)/503 induces resistance to anti-cancer therapy due to up-regulation of BCL-2 and IGF1R. (A) Mammary
tumor volumes emerging inMMTV-Neu andMMTV-Neu-miR_KO animals weremonitored until they reached ∼500mm3, and then an-
imals were treated twice per week with paclitaxel (PTX). (B) Growth curves showing the response to paclitaxel treatment. (C ) Cleaved
Caspase-3 immunostaining in tumors from MMTV-Neu and MMTV-Neu-miR_KO models after treatment with paclitaxel. (D) Illustra-
tion of the strategy to evaluate the use of ABT-199 and BMS-754807 to reverse chemoresistance in MMTV-Neu-miR_KO animals. (E)
Growth curves showing the response to paclitaxel alone versus paclitaxel plus BMS-754807 and ABT-199. (F ) Cleaved Caspase-3 immu-
nostaining in the MMTV-Neu-miR_KO tumors from E. For animal studies, five to eight animals were used per cohort.
miR-424/503 is a breast cancer tumor suppressor
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have been completed, demonstrating safety and tolera-
bility (https://clinicaltrials.gov/ct2/results?term=BMS-
754807&Search=Search).
Previously, we showed that miR-424(322)/503−/−
mousemammary epithelial cells (MMECs) aremore resis-
tant to chemotherapeutic agents such as paclitaxel than
wild-type counterparts (see also Supplemental Fig. S4B;
Llobet-Navas et al. 2014a). Thus, we first tested whether
treating these cells with the above-mentioned inhibitors
would resensitize them. Interestingly, treating these cells
with each individual inhibitor increased their sensitivity
to paclitaxel, and this effect was increased when they
were combined (Supplemental Fig. S4C). Based on these
data, we next compared the response of MMTV-Neu-
miR_KO mice treated with paclitaxel alone (as described
above) versus animals treated with paclitaxel plus ABT-
199 and BMS-754807 administered by gavage at 50 mg/
kg three times per week (Fig. 4D; Supplemental Fig.
S4D; Hou et al. 2011; Vaillant et al. 2013). Remarkably,
blocking IGF1R activation and BCL-2 through the use of
these inhibitors resensitized MMTV-Neu-miR_KO tu-
mors to paclitaxel (Fig. 4E; Supplemental Fig. S4E), and
the tumors showed a significant increase in treatment-in-
duced apoptosis (Fig. 4F). No significant differences in the
response to paclitaxel were observed when parental
MMTV-Neu tumors were treated with these inhibitors
(Supplemental Fig. S4F).
Based on the results from our animal models shown
above, we postulated that the unfavorable prognosis of
loss of the miR-424(322)/503 locus could be mediated at
least in part by the poor response of miR-424(322)/503-de-
ficient cells to treatment. Thus, we analyzed the prognos-
tic value of miR-424(322)/503 loss in our data set
according to the delivery or lack of adjuvant chemothera-
py; that is, we searched for an association between miR-
424(322)/503 status and the benefit of chemotherapy in
terms of overall survival. In univariate analysis, an inter-
action was observed in the whole population (P = 0.02):
In the chemotherapy-naïve subgroup, patients with
“miR-DEL” and patients with “miR-non-DEL” tumors
exhibited similar overall survival (P = 0.16, Wald test),
whereas, in the chemotherapy-treated subgroup, patients
with “miR-DEL” tumors exhibited shorter overall sur-
vival than patients with “miR-non-DEL” tumors (P =
1.61 × 10−4, Wald test) (Fig. 5A; Table 1). Therefore, expo-
sure to chemotherapy was associated with a lesser risk of
death and consequently a stronger benefit in patients with
“miR-non-DEL” tumors (HR = 1.67 [95%CI 1.32–2.12]; P
= 2.06 × 10−5) than in patients with “miR-DEL” tumors
(HR = 2.74 [95% CI 1.76–4.27]). Analysis per molecular
subtype revealed a similar trend in the basal subtype (P
= 0.09) (Fig. 5B; Table 1), while lesser or no effect was ob-
served in other molecular subtypes (Supplemental Table
S4). Importantly, inmultivariate analysis (Table 1), the in-
teraction remained significant in the whole population (P
= 1.58 × 10−3) and tended toward significance in the basal
subtype (P = 0.10). Thus, these data confirm that, in breast
cancer, the status of the miR-424(322)/503 cluster is asso-
ciated with reduced response to chemotherapy, particu-
larly in the basal subtype.
Discussion
Transformation of normal cells is driven by the aberrant
function of genes that positively (oncogenes) and nega-
tively (tumor suppressors) regulate the cancer phenotype
(Hanahan and Weinberg 2011). Identification and charac-
terization of those genes that provide cells with the capa-
bilities necessary for tumor initiation and progression are
critical to understanding tumorigenesis. The identifica-
tion of tumor suppressors has been historically challeng-
ing due to their recessive nature and the diverse
mechanisms by which they are inactivated. Here we re-
port the tumor suppressor function of the miR-424(322)/
503 cluster in breast cancers.
The miR-424(322)/503 cluster expresses miR-424(322)
and miR-503, two miRNAs that belong to the miR-16
family. In humans, this family consists of at least 10mem-
bers that have been shown to regulate an array of processes
such as cell division, metabolism, stress response, and an-
giogenesis (Finnerty et al. 2010). Two of its members,
miR-15a and miR-16-1, have been associated previously
with tumor suppressor functions mainly in blood cancers
(Aqeilan et al. 2010; Finnerty et al. 2010). Although a role
for miR-424 and miR-503 in tumorigenesis has been
Figure 5. The impact of miR-424(322)/503
loss on the overall survival of breast cancer pa-
tients depends on chemotherapy treatment.
(A) Overall survival of breast cancer patients
(METABRIC and TCGA data sets) with and
without deletion of the miR-424(322)/503 lo-
cus and with (+chemo) and without (−chemo)
delivery of adjuvant chemotherapy. (B) Similar
toA, but limited to patients with basal tumors.
The statistical studies shown represent univar-
iate analysis. Values for both univariate and
multivariate analysis are shown in Table 1.
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suggested, these studies are conflicting, and both tumor-
suppressing (Xu et al. 2013a; Chong et al. 2014; Li et al.
2015) and tumor-promoting (Zhang et al. 2014; Ide et al.
2015) functions have been proposed. Arguably, a key rea-
son for this discrepancy was that previous reports were
based mainly on association studies in which miRNA ex-
pression was compared between cancerous and noncan-
cerous tissues. Additionally, functional studies were
limited to the use of cell lines in which miR-424 and
miR-503 were overexpressed. Here, through the use of a
knockout mouse model, we demonstrate for the first
time that loss of miR-424(322)/503 promotes breast tu-
morigenesis in vivo and describe the genetic aberrations
that inactivate its expression in human breast cancers.
Notably, according to our knowledge, this is the first re-
port of a miRNA with tumor suppressor functions that
is able to generate solid tumors in mice when deleted
without the use of cooperating alterations (e.g., P53-null
orMYC-overexpressing mouse strains).
How does loss of miR-424(322)/503 impact mammary
tumorigenesis and tumor progression? Our previous stud-
ies (Llobet-Navas et al. 2014a,b) and the new data shown
here have revealed that this miRNA cluster modulates
the expression of at least three well-known oncogenes
(CDC25A, BCL-2, and IGF1R) in human and mouse
primary breast cancers. Others have also shown that, in
other cell types, this cluster targets additional genes in-
volved in cell cycle progression (Nakashima et al. 2010;
Xu et al. 2013b), angiogenesis (Ghosh et al. 2010; Naka-
shima et al. 2010), immune response (Xu et al. 2016),
cell metabolism (Long et al. 2013), and cell adhesion
(Chong et al. 2014). Thus, we propose that aberrant
high levels of these targets due to loss of miR-424(322)/
503 support multiple hallmarks of cancer leading to tu-
morigenesis (Fig. 6A).
Chemoresistance is one of the most pressing problems
faced by oncologists (Raguz and Yague 2008). Despite the
general use of chemotherapy as the standard of care in the
vast majority of anti-cancer regimens, life-threatening in-
trinsic and acquired resistance commonly emerges (Wil-
son et al. 2006). In breast cancers, this is especially
problematic for patients whose tumors are of the TN
and basal subtypes. As these tumors do not express ste-
roid hormone receptors or present alterations in the
HER2 oncogene, they cannot benefit from targeted ther-
apies specifically designed against these cancer determi-
nants. Thus, chemotherapy remains the only possible
therapeutic option in the adjuvant or metastatic setting
for these patients (Gluz et al. 2009; Brunello et al.
2013). The studies presented here have revealed that
loss of miR-424(322)/503 occurs in ∼20% of TN and basal
breast cancers and is associated with shorter overall sur-
vival independent of clinicopathological variables. Im-
portantly, we linked the influence of miR-424(322)/503
loss on patient survival with the induction of chemore-
sistance due to the aberrant up-regulation of defined
miR-424(322)/503 targets. Our deep understanding and
characterization of the miR-424(322)/503–target axes in
the normal mammary epithelium (Llobet-Navas et al.
2014a,b) as well as in breast cancers have allowed us to
propose targeted therapy-based combinations to block
the activity of IGF1R and BCL-2 and effectively reverse
chemoresistance (Fig. 6B). Remarkably, inhibitors such
as ABT-199 or BMS-754807 that are currently under in-
vestigation in clinical trials and show promising anti-can-
cer activity and low toxicity represent an exciting and
realistic therapeutic opportunity for patients who present
chemoresistance due to the loss of miR-424(322)/503. To
this end, we performed toxicological studies in our pre-
clinical animal models. This analysis revealed that addi-
tion of ABT-199 and BMS-754807 to paclitaxel treatment
did not change the total white blood cell count but re-
duced the leucocyte fraction while increasing the per-
centage of neutrophils and monocytes. Chemical tests
also showed a comparable pattern with a few exceptions
(Supplemental Table S5).
There are some questions that are still unanswered due
to limitations in our study and are worth discussing. We
focused our studies on the impact that aberrant up-
Figure 6. Model of transformation and induction of chemore-
sistance mediated by loss of miR-424(322)/503. (A) The miRNA
cluster miR-424(322)/503 modulates the expression of multiples
genes (including well-known oncogenes) that regulate various
processes associated with tumorigenesis such as cell cycle pro-
gression, angiogenesis, immune response, cell metabolism, and
cell adhesion. Note that a role for miR-424(322) and miR-503 in
angiogenesis and immune evasion has been reported but was
not evaluated in this study. Cells deficient in miR-424(322)/503
present aberrant high levels of these targets, leading to tumori-
genesis. As some of these targets are controlled by the miR-424
(322)/503 cluster during regression of the post-partummammary
epithelium, we propose that miR-424(322)/503-deficient cells are
especially sensitive to transformation during pregnancy. (B) Loss
of miR-424(322)/503 induces up-regulation of BCL-2 and IGF1R,
which in turn promotes chemoresistance. Specific inhibitors
against these proteins resensitized cancer cells to chemotherapy,
representing a targeted therapeutic opportunity.
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regulation of miR-424(322)/503 targets has on chemore-
sistance, but, at this point, we do not know which of the
targets is responsible for the formation of mammary tu-
mors observed in the miR-424(322)/503−/− animals. Inter-
estingly, elevated levels of CDC25A in the MMTV-
CDC25A model cause alveolar hyperplasia and reduce
the latency of mammary tumorigenesis in MMTV-Ras
mice (Galaktionov et al. 1996; Ray et al. 2007). Overex-
pression of BCL-2 in the WAP-TAg transgenic mouse
model of breast cancer also accelerates tumorigenesis
(Furth et al. 1999). Finally, overexpression of IGF1R in-
duces tumor formation in a doxycycline-inducible
MMTV-IGF1R model (Jones et al. 2007). Thus, it is possi-
ble that one of these oncogenes, the combination of some
of them, or other unidentified targets may be involved in
the observed tumorigenesis. Additional genetic studies in
which these targets are abrogated individually and in com-
bination in the miR_KO model and breast tumorigenesis
is compared will be necessary to answer this question.
The miR-424(322)/503 cluster expresses two miRNAs.
Is the loss of both miRNAs important for breast tumori-
genesis and chemoresistance? The knockout mouse mod-
el used here presents a deletion of both miRNAs and
consequently does not allow for investigation of the con-
tribution of each miRNA independently. We generated a
small cohort of knockout mice containing the deletion
of only one miRNA. We found that, in these animals,
the expression of the remaining maturemiRNAwas bare-
ly detectable (Llobet-Navas et al. 2014a). This result,
which suggests that the sequence/structure of the miR-
424(322)/503 primary transcript is essential for proper
generation of mature miRNAs, prevents, at least in the
generated models, further studies of the individual miR-
NAs in vivo. We and others have reported previously
that miR-424(322) and miR-503 regulate a similar list of
putative targets and can cooperate to down-regulate
expression of their targets in vitro (Rissland et al. 2011;
Llobet-Navas et al. 2014a,b). Moreover, we reported previ-
ously that individual experimental up-regulation of miR-
424(322) and miR-503 is able to attenuate the expression
of BCL-2 and IGF1R at a comparable level (Llobet-Navas
et al. 2014b). Thus, we hypothesize that the loss of both
miRNAs in the cluster contributes to the cancer pheno-
type. Nonetheless, the deletions observed in breast cancer
involve loss of both miRNAs concurrently.
Finally, as the miR-424(322)/503 cluster is involved in
involution of the mammary epithelium after pregnancy
(Llobet-Navas et al. 2014a) and as our new data show
that tumorigenesis in miR-424(322)/503−/− female mice
is promoted by pregnancy, our results also suggest, al-
though not fully prove, a molecular link between preg-
nancy and breast cancers. In this regard, it will be
interesting to investigate whether breast cancers present-
ing loss of miR-424(322)/503 are more frequent in parous
compared with nulliparous women and whether the
number of pregnancies influences any potential disparity.
Unfortunately, there is no reproductive history in the
available data sets (including TCGA-BRCA and META-
BRIC), and additional studies will be necessary to answer
this question.
Overall, our studies reveal the followingmajor discover-
ies: First, we unambiguously demonstrated the tumor
suppressor function of miR-424(322)/503 in breast can-
cers. Second, we uncovered the impact that loss of miR-
424(322)/503 has on promoting chemoresistance. Finally,
ourmolecular understanding of the genes regulated by the
miR-424(322)/503 cluster identified therapeutic strategies
to restore sensitivity to chemotherapy.
Materials and methods
Cell culture
All cell lines were obtained fromAmerican Type Culture Collec-
tion and Invitrogen and grown as recommended (detailed in the
Supplemental Material).
Western blotting
Samples were lysed with EZ lysis buffer (1 M Tris at pH 7, 50%
glycerol, 20% SDS, 1 mM sodium orthovanadate, 1 mM sodium
fluoride, 1 mM phenylmethylsulfonyl fluoride). Protein concen-
trations were determined using the protein assay kit (Bio-Rad,
500-0006). Equal amounts of proteins were subjected to SDS-
PAGE and transferred to nitrocellulose membranes (GE Health-
care, 10401197). Membranes were incubated overnight at 4°C
with primary antibodies and for 1 h at room temperaturewith sec-
ondary HRP-conjugated antibodies. The antibodies used in this
study include IGF1R, BCL-2, and CDC25A from Santa Cruz Bio-
technology (sc-492, sc-713, and sc-7389, respectively); p-Akt
Ser473, p-IGF1R Tyr1131, and p-IGF1R Tyr1135 from Cell Sig-
naling (4060, 3021, and 3918, respectively); and β-Actin from
US Biological (A0760-40).
Experimental animals
Animal maintenance and experiments were performed in accor-
dance with the animal care guidelines and protocols approved
by the Columbia University/Mount Sinai animal care units.
Mixed background miR-424(322)/503−/− females were retro-
crossed for 10 generations with FvB/NJ males (Jackson, 001800)
to ensure a homogeneous FvB/NJ background. Genotyping was
performed on tail samples using the Direct PCR reagent (Viagen,
202-Y). Tails were incubated in 250 µL of Direct PCR reagent and
20 mg/mL Proteinase K (New England Biolabs, P8102) for 5 h at
55°C. Samples were then incubated for 45 min at 85°C, after
which they were centrifuged at full speed for 5 min. One microli-
ter of samplewas used to perform genotyping PCR using the Fast-
Start polymerase (Roche, 04738420001). Thermal conditions
were as follows: predenaturing for 5 min at 94°C, 35× (denaturing
for 30 sec at 94°C, annealing for 30 sec at 55°C, and elongation for
30 sec at 72°C), and final elongation for 7 min at 72°C. All exper-
iments were performed under the Institutional Animal Care and
Use Committee (IACUC) guidelines.
Primers used for genotyping were as follows: pair 1 (F, CACC
AGCAGATCCTGGAAAT; R, CAAGTGAGGCGCTAACAA
CA) and pair 2 (F, AGTTTCGAAAAACGGACATA; R, ATT
GCCTCTCATTGTACCAC).
FvB/NJ miR-424(322)/503−/− mice were crossed with MMTV-
Neu mice (NK1Mul/J; Jackson, 005038) to study the effects of
miR-424(322)/503 targeted deletion in mammary breast tumor
growth, latency, and response to chemotherapy.
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GENES & DEVELOPMENT 563
 Cold Spring Harbor Laboratory Press on April 19, 2017 - Published by genesdev.cshlp.orgDownloaded from 
Drug administration
Paclitaxel (obtained from Columbia University Medical Center-
Presbyterian Hospital) was diluted with PBS to 6 mg/mL. ABT-
199 and BMS-754807 were purchased from Selleckchem. Pacli-
taxel (6 mg/kg) was administered intraperitoneally twice per
week for 3 wk, and the combination 50 mg/kg ABT-199 + 50
mg/kg BMS-754807 was administered by gavage three times per
week for 3 wk. Animals were monitored for 3 wk, and tumor vol-
umewasmeasured twice perweek using the ellipsoid volume for-
mula 1/2 × L ×W×H.
ChIP
A standard immunoprecipitation protocol was followed. The de-
tailed protocol is described in the Supplemental Material.
Monoallelic expression
Genomic DNA (Qiagen, 13323) and total RNA (Qiagen, 74104)
were extracted from 184B5 and primary HuMECs according to
the manufacturer’s recommendations (Agilent, 400800). Total
RNA (0.5 µg) was converted into cDNA using the high-capacity
cDNA reverse transcription kit (Roche, 4368814). Genomic
DNA and cDNA were amplified using specific primers (F,
TTCAGTCATCCAGTCTTTATTCA; and R, GATGGCCTAA-
GACTTACCTGCT) at the miR-424/503 locus and flanking the
SNP Rs757309. PCR products were analyzed by Sanger
sequencing.
Patient samples and data analysis
Patient data were assessed from METABRIC and TCGA corre-
sponding to breast cancer samples with available whole-genome
DNA CNAs, mRNA expression data, and clinicopathological
data. TCGA samples were profiled using Affymetrix SNP 6.0 ar-
rays and Agilent G4502A custom microarrays, and METABRIC
samples were profiled using Affymetrix SNP 6.0 arrays and
Illumina HT-12 microarrays. These sets were collected from
the TCGA Data Portal (https://tcga-data.nci.nih.gov/tcga) and
the European Genome–Phenome Archive (EGA) database
(EGAS00000000083). The TCGA data set also included level 3
methylation profiling data obtained on the Illumina HumanMe-
thylation450 platform and downloaded from the University of
California at Santa Cruz Cancer Browser (https://genome-
cancer.ucsc.edu) and RPPA data with expression levels for ∼200
proteins. Array-CGH data were analyzed defining breast cancers
with (“miR-DEL”) versus without (“miR-non-DEL”) miR-424
(322)/503 deletion. Patients’ data analysis is described in detail
in the Supplemental Material.
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